Table 3A.
Univariate cox regression of all patients and variables effect on progression-free survival and overall survival.
| Variable | PFS | OS | ||
|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | |
| Age (≥65 vs <65) | 1.91(0.85-3.02) | 0.04 | 1.67(0.81-1.93) | 0.03 |
| Gender (Male vs Female) | 1.02(0.67-1.55) | 0.94 | 1.01(0.63-1.64) | 0.93 |
| ECOG (≥2 vs 0-1) | 2.15(1.95-3.08) | 0.02 | 2.43(1.87-3.34) | 0.03 |
| BRAF status (BRAF wt vs BRAF mutated) | 0.85(0.55-1.30) | 0.45 | 0.79(0.51-1.21) | 0.28 |
| Number of metastasis during first-line treatment(≥2 vs 1) | 2.11(0.97-4.14) | 0.21 | 1.98(1.09-3.62) | 0.03 |
|
Brain metastases
(Yes vs No) |
2.01(1.26-3.21) | <0.01 | 2.07(1.29-3.32) | <0.01 |
|
Liver metastases
(Yes vs No) |
1.55(0.90-2.68) | 0.03 | 1.42(0.82-2.46) | 0.08 |
|
LDH level
(Normal vs Elevated) |
0.60(0.26-1.42) | 0.03 | 0.44(0.19-1.03) | 0.06 |
|
Second-line therapy received
(Yes vs No) |
1.51(0.97-2.30) | 0.14 | 1.31(0.87-2.01) | 0.20 |